The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > 2019 > 12 > FDA Finalizes Guidance on Adaptive Trial Designs

FDA Finalizes Guidance on Adaptive Trial Designs

Posted 02 December 2019 | By Michael Mezher 

FDA Finalizes Guidance on Adaptive Trial Designs

The US Food and Drug Administration (FDA) last week finalized guidance on adaptive clinical trial designs for drugs and biologics.
The 33-page guidance, which finalizes a draft version released for comment in September 2018 and replaces an earlier guidance from 2010, sets out FDA’s recommendations on adaptive trial design principles and the information FDA will review from adaptive studies submitted as part of investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs) and supplemental applications.
While the final guidance is largely the same as the draft version, FDA says it has revised the guidance to clarify its recommendations for Bayesian adaptive designs and its expectations for the extent of prespecification required for governing adaptations to studies in addition to minor editorial changes.
The final guidance also refers sponsors to review FDA’s September 2019 draft guidance on complex innovative trial designs for more information on trial design proposals that use Bayesian inference.
Additionally, while FDA recommends that sponsors prespecify rules governing trial adaptations, the agency acknowledges that “monitoring committee recommendations might occasionally deviate from the anticipated algorithm based on the totality of the data.” The agency also says that if sponsors desire flexibility adjusting these deviations to their prespecified plan, they “should acknowledge the possibility of deviations from the anticipated algorithm, outline factors that may lead to such deviations, and propose testing and estimation methods that do not rely on strict adherence to the algorithm.”
In the Federal Register notice announcing the final guidance, FDA says it expects to see approximately 240 documented plans for clinical trials with an adaptive design and analysis plan from 40 sponsors annually.
FDA also says it expects to receive about 20 marketing applications for drugs and biologics from 15 sponsors that rely on data from an adaptive study each year.


© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.